The study presents a comprehensive approach to drug discovery in the context of AML, specifically targeting FLT3 activation loop mutants, utilizing the ConPLex platform for a large-scale analysis of millions of inhibitor combinations. Here, FLT3 is linked to acute myeloid leukemia.